Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals

• Published in: Hepatology communications Vol. 7; no. 3; p. e0005
• Main Authors: Ng, Cheng Han, Tang, Ansel Shao Pin, Xiao, Jieling, Wong, Zhen Yu, Yong, Jie Ning, Fu, Clarissa E., Zeng, Rebecca W., Tan, Caitlyn, Wong, Gabriel Hong Zhe, Teng, Margaret, Chee, Douglas, Tan, Darren Jun Hao, Chan, Kai En, Huang, Daniel Q., Chew, Nicholas W.S., Nah, Benjamin, Siddqui, Mohammad S., Sanyal, Arun J., Noureddin, Mazen, Muthiah, Mark
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01.03.2023; Wolters Kluwer Health/LWW
• Subjects: Chenodeoxycholic Acid - adverse effects; Humans; Longitudinal Studies; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - epidemiology; Original; Pruritus - drug therapy

Obeticholic acid (OCA) is a farnesoid X receptor agonist used in primary biliary cholangitis (PBC) treatment. Recent studies have expanded OCA use for NASH treatment and results from phase 3 clinical trial have shown beneficial reduction of ≥1 stage of fibrosis with no NASH worsening. However, safet...